Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):97–102. doi: 10.1038/bjc.1993.293

Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

S O Andersson 1, H O Adami 1, R Bergström 1, L Wide 1
PMCID: PMC1968302  PMID: 8318428

Abstract

The hypothesis that serum concentrations of pituitary hormones, sex steroid hormones, or sex hormone-binding globulin (SHBG) affect the occurrence of prostatic cancer was tested in a consecutive sample of 93 patients with newly diagnosed, untreated cancer and in 98 population controls of similar ages without the disease. Cases did not differ significantly from controls regarding serum levels of luteinising hormone (LH) or follicle stimulating hormone (FSH). Remarkably close agreement was found for mean values of total testosterone (15.8 nmol l-1 in cases and 16.0 in controls), and free testosterone (0.295 and 0.293 nmol l-1, respectively), with corresponding odds ratios for the highest vs lowest tertile of 1.0 (95% confidence interval 0.5-1.9) for testosterone and 1.2 (95% confidence interval 0.6-2.4) for free testosterone. Similar close agreement between cases and controls was found for serum concentrations of estradiol, androstenedione and SHBG, although the mean estradiol level was non-significantly (P = 0.30) lower among cases. Changes secondary to the disease were unlikely to have affected the results materially, since only LH and FSH were associated with stage of disease and this relationship was weak. Our findings suggest that further analyses of serum hormone levels at the time of diagnosis are unlikely to improve our understanding of the etiology of prostatic cancer.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia B., Jackson M. A., Jones G. W., Williams A. O., Rao M. S., Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer. 1981 Nov 15;48(10):2267–2273. doi: 10.1002/1097-0142(19811115)48:10<2267::aid-cncr2820481023>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  2. Barrack E. R., Bujnovszky P., Walsh P. C. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res. 1983 Mar;43(3):1107–1116. [PubMed] [Google Scholar]
  3. Barrett-Connor E., Garland C., McPhillips J. B., Khaw K. T., Wingard D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990 Jan 1;50(1):169–173. [PubMed] [Google Scholar]
  4. Bartsch W., Horst H. J., Becker H., Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh) 1977 Jul;85(3):650–664. doi: 10.1530/acta.0.0850650. [DOI] [PubMed] [Google Scholar]
  5. Bartsch W., Steins P., Becker H. Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur Urol. 1977;3(1):47–52. doi: 10.1159/000472054. [DOI] [PubMed] [Google Scholar]
  6. Coffey D. S., Isaacs J. T. Control of prostate growth. Urology. 1981 Mar;17(Suppl 3):17–24. [PubMed] [Google Scholar]
  7. Dai W. S., Kuller L. H., LaPorte R. E., Gutai J. P., Falvo-Gerard L., Caggiula A. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol. 1981 Dec;114(6):804–816. doi: 10.1093/oxfordjournals.aje.a113251. [DOI] [PubMed] [Google Scholar]
  8. Drafta D., Proca E., Zamfir V., Schindler A. E., Neacşu E., Stroe E. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem. 1982 Dec;17(6):689–693. doi: 10.1016/0022-4731(82)90572-6. [DOI] [PubMed] [Google Scholar]
  9. Ghanadian R., Puah C. M., O'Donoghue E. P. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer. 1979 Jun;39(6):696–699. doi: 10.1038/bjc.1979.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Habib F. K. Evaluation of androgen metabolism studies in human prostate cancer--correlation with zinc levels. Prev Med. 1980 Sep;9(5):650–656. doi: 10.1016/0091-7435(80)90036-5. [DOI] [PubMed] [Google Scholar]
  11. Habib F. K., Odoma S., Busuttil A., Chisholm G. D. Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor. Cancer. 1986 Jun 15;57(12):2351–2356. doi: 10.1002/1097-0142(19860615)57:12<2351::aid-cncr2820571219>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  12. Hammond G. L., Kontturi M., Vihko P., Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol (Oxf) 1978 Aug;9(2):113–121. doi: 10.1111/j.1365-2265.1978.tb02189.x. [DOI] [PubMed] [Google Scholar]
  13. Harper M. E., Peeling W. B., Cowley T., Brownsey B. G., Phillips M. E., Groom G., Fahmy D. R., Griffiths K. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh) 1976 Feb;81(2):409–426. doi: 10.1530/acta.0.0810409. [DOI] [PubMed] [Google Scholar]
  14. Hill P., Wynder E. L., Garbaczewski L., Walker A. R. Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res. 1982 Sep;42(9):3864–3869. [PubMed] [Google Scholar]
  15. Hulka B. S., Hammond J. E., DiFerdinando G., Mickey D. D., Fried F. A., Checkoway H., Stumpf W. E., Beckman W. C., Jr, Clark T. D. Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate. 1987;11(2):171–182. doi: 10.1002/pros.2990110208. [DOI] [PubMed] [Google Scholar]
  16. Høisaeter P. A., Haukaas S., Bakke A., Hoiem L., Segadal E., Thorsen T. Blood hormone levels related to stages and grades of prostatic cancer. Prostate. 1982;3(4):375–381. doi: 10.1002/pros.2990030407. [DOI] [PubMed] [Google Scholar]
  17. Ishikawa S., Soloway M. S., Van der Zwaag R., Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol. 1989 May;141(5):1139–1142. doi: 10.1016/s0022-5347(17)41193-1. [DOI] [PubMed] [Google Scholar]
  18. Jackson M. A., Kovi J., Heshmat M. Y., Ogunmuyiwa T. A., Jones G. W., Williams A. O., Christian E. C., Nkposong E. O., Rao M. S., Jackson A. G. Characterization of prostatic carcinoma among blacks: a comparison between a low-incidence area, Ibadan, Nigeria, and a high-incidence area, Washington, DC. Prostate. 1980;1(2):185–205. doi: 10.1002/pros.2990010205. [DOI] [PubMed] [Google Scholar]
  19. Jacobi G. H., Rathgen G. H., Altwein J. E. Serum prolactin and tumors of the prostate: unchanged basal levels and lack of correlation to serum testosterone. J Endocrinol Invest. 1980 Jan-Mar;3(1):15–18. doi: 10.1007/BF03348211. [DOI] [PubMed] [Google Scholar]
  20. Meikle A. W., Smith J. A., Stringham J. D. Estradiol and testosterone metabolism and production in men with prostatic cancer. J Steroid Biochem. 1989 Jul;33(1):19–24. doi: 10.1016/0022-4731(89)90352-x. [DOI] [PubMed] [Google Scholar]
  21. Meikle A. W., Stanish W. M. Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab. 1982 Jun;54(6):1104–1108. doi: 10.1210/jcem-54-6-1104. [DOI] [PubMed] [Google Scholar]
  22. Noble R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977 Jun;37(6):1929–1933. [PubMed] [Google Scholar]
  23. Nomura A., Heilbrun L. K., Stemmermann G. N., Judd H. L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 1988 Jun 15;48(12):3515–3517. [PubMed] [Google Scholar]
  24. Rannikko S., Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate. 1983;4(3):223–229. doi: 10.1002/pros.2990040302. [DOI] [PubMed] [Google Scholar]
  25. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  26. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed] [Google Scholar]
  27. Saroff J., Kirdani R. Y., Chu T. M., Wajsman Z., Murphy G. P. Measurements of prolactin and androgens in patients with prostatic diseases. Oncology. 1980;37(1):46–52. doi: 10.1159/000225401. [DOI] [PubMed] [Google Scholar]
  28. Södergård R., Bäckström T., Shanbhag V., Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982 Jun;16(6):801–810. doi: 10.1016/0022-4731(82)90038-3. [DOI] [PubMed] [Google Scholar]
  29. Young H. H., 2nd, Kent J. R. Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol. 1968 Jun;99(6):788–792. doi: 10.1016/S0022-5347(17)62795-2. [DOI] [PubMed] [Google Scholar]
  30. Zumoff B., Levin J., Strain G. W., Rosenfeld R. S., O'Connor J., Freed S. Z., Kream J., Whitmore W. S., Fukushima D. K., Hellman L. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory. Prostate. 1982;3(6):579–588. doi: 10.1002/pros.2990030607. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES